Back to Search Start Over

The L1624Q Variant in SCN1A Causes Familial Epilepsy Through a Mixed Gain and Loss of Channel Function.

Authors :
Jones LB
Peters CH
Rosch RE
Owers M
Hughes E
Pal DK
Ruben PC
Source :
Frontiers in pharmacology [Front Pharmacol] 2021 Dec 02; Vol. 12, pp. 788192. Date of Electronic Publication: 2021 Dec 02 (Print Publication: 2021).
Publication Year :
2021

Abstract

Variants of the SCN1A gene encoding the neuronal voltage-gated sodium channel Na <subscript>V</subscript> 1.1 cause over 85% of all cases of Dravet syndrome, a severe and often pharmacoresistent epileptic encephalopathy with mostly infantile onset. But with the increased availability of genetic testing for patients with epilepsy, variants in SCN1A have now also been described in a range of other epilepsy phenotypes. The vast majority of these epilepsy-associated variants are de novo , and most are either nonsense variants that truncate the channel or missense variants that are presumed to cause loss of channel function. However, biophysical analysis has revealed a significant subset of missense mutations that result in increased excitability, further complicating approaches to precision pharmacotherapy for patients with SCN1A variants and epilepsy. We describe clinical and biophysical data of a familial SCN1A variant encoding the Na <subscript>V</subscript> 1.1 L1624Q mutant. This substitution is located on the extracellular linker between S3 and S4 of Domain IV of Na <subscript>V</subscript> 1.1 and is a rare case of a familial SCN1A variant causing an autosomal dominant frontal lobe epilepsy. We expressed wild-type (WT) and L1642Q channels in CHO cells. Using patch-clamp to characterize channel properties at several temperatures, we show that the L1624Q variant increases persistent current, accelerates fast inactivation onset and decreases current density. While SCN1A -associated epilepsy is typically considered a loss-of-function disease, our results put L1624Q into a growing set of mixed gain and loss-of-function variants in SCN1A responsible for epilepsy.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Jones, Peters, Rosch, Owers, Hughes, Pal and Ruben.)

Details

Language :
English
ISSN :
1663-9812
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
34925043
Full Text :
https://doi.org/10.3389/fphar.2021.788192